Science Abstracts
Deforolimus (AP23573) a novel mTOR inhibitor in clinical development
December 2008
December 2008
Authors : Monica Mita , Kamalesh Sankhala , Issam Abdel-Karim , Alain Mita , Francis Giles
Affliation : Institute for Drug Development, Cancer Therapy and Research Center, UT Health Science Center, San Antonio ; ; mitam@uthscsa.edu
DOI : 10.1517/13543780802556485
Published in : Expert Opin. Investig. Drugs Volume 17 Issue 12 2008 pages 1947 1954
Subject:
Keywords: clinical trials , deforolimus , mTOR inhibitor , rapamycin , sarcoma
Abstract
mTOR was determined to be a promising anticancer...
Please Login to read the full article.
RELATED CONTENT
NEWS
- YM BioSciences rises on PhI/II results showing promise for JAK1/JAK2 inhibitor for myelofibrosis
- Peregrine flies with positive Phase II bavituximab lung cancer data
- US Capitol Capsule: Obama jobs push may bode well for patent reform
- Aeterna's test for adult growth hormone deficiency reaches goal in PhIII study
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
